Twin to twin transfusion syndrome (TTTS) is a major complication of monochorionic diamniotic (MD) twins, and its onset is known to be associated with placental vascular anastomoses and blood flow imbalance. In a typical case of TTTS, the recipient develops polyhydramnios, weight gain, cardiomegaly and hydrops fetalis in the uterus. In contrast, the donor develops oligohydramnios and intrauterine growth restriction. Recently, the significance of the renin-angiotensin-aldosterone system (RAAS) that transfers from the donor to the recipient has attracted interest in the fetal circulation of TTTS. The donor has decreased renal blood flow due to decreased circulating blood volume. For this reason, the secretion of RAAS hormones is augmented in the fetal kidneys of the donor. In TTTS, these RAAS hormones from the donor transfer to the recipient through the anastomosed vessels. In addition to excess preload, the recipient heart is exposed to excess afterload due to systemic vasoconstriction through RAAS hormones. Commonly occurring complications in the recipient include myocardial hypertrophy, atrioventricular valve regurgitation, and pulmonary valve stenosis or pulmonary atresia. Fetoscopic laser photocoagulation (FLP) has been introduced recently because neither mortality nor neurological morbidity have been satisfactorily improved with conventional treatment. FLP is a curative method that may improve the prognosis of TTTS. In Japan, this procedure has been performed frequently, and positive neurological outcomes have been achieved. (J Nippon Med Sch 2019; 86: 192 200) 
Pathology and Definition of TTTS
Twin to twin transfusion syndrome (TTTS) is a complication that is observed in about 10 to 30% of monochorionic diamniotic (MD) twins 1 3 , and its onset is known to be associated with placental vascular anastomoses and blood flow imbalance. Twins in TTTS are commonly referred to as the recipient or the donor. In a typical case of TTTS, the recipient develops polyhydramnios, weight gain, cardiomegaly, and effusion into body cavity (hydrops fetalis) during the fetal stage and shows signs such as plethora, hypertension, polyuria, cardiomegaly, and hydrops fetalis postnatally. In contrast, the donor develops oligohydramnios and fetal growth restriction during the fetal stage and shows signs such as anemia, oliguria, renal failure, and oligohydramnios sequence postnatally.
There is, however, a broad spectrum of signs and symptoms in TTTS. Classically, TTTS was evaluated based on observing the differences in birth weight or in hemoglobin level in the neonates 4, 5 . However, with the advances and widespread use of ultrasound examinations, TTTS is currently diagnosed by assessing the presence of twin of oligohydramnios-polyhydramnios sequence (TOPS), a condition in which monochorionic twins present an excess and deficiency of amniotic fluid during the fetal stage 6 . Consequently, it has become standard practice to define TTTS as MD twins presenting abnormally large and small volumes of amniotic fluid with maximum vertical pockets of >8 cm and <2 cm, respectively. The staging system proposed by Quintero et al. 7 classifies the progression of TTTS as follows: 1) presence of amniotic fluid Table 1 Staging of TTTS based on sonographic and doppler findings 5 . Quintero RA
Stage
Poly/oligohydramnios* Absent bladder in donor CADs † Hydrops  Demise   I  +  ----I I  +  +  ---III  +  +  +  --IV  +  +  +  +  -V  +  +  + (Table 1) . This staging is also used to determine when to start treatment using the recentlydeveloped selective fetoscopic laser photocoagulation (FLP) to ablate placental anastomoses in the fetus and to assess the effects of such treatment 8 .
Hemodynamics and Endocrine Environment in TTTS
Recently, the significance of the renin-angiotensinaldosterone system (RAAS) that transfers from the donor to the recipient has attracted interest in the fetal circulation of TTTS 9 . As described above, the recipient and donor share one placenta in TTTS, and there is a chronic transfer of blood from the donor to the recipient via vascular anastomoses. This results in a volume overload in the recipient and the opposite in the donor. Increased circulating blood volume in the recipient leads to excess preload. For this reason, there is augmented secretion of natriuretic peptides such as atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) and of endothelin 1, inducing an increase in urine production 10 . On the other hand, the donor has decreased renal blood flow due to decreased circulating blood volume, causing a decrease in fetal urine. For this reason, the secretion of renin/angiotensin/aldosterone system, known as RAAS hormones, is augmented in the fetal kidneys of the donor. In TTTS, these RAAS hormones from the donor transfer to the recipient through the anastomosed vessels.
This raises the levels of RAAS hormones in the recipient even though the recipient has an elevated circulating blood volume, and this consequently triggers a "paradoxical RAAS activation," also known as the "two-kidney one-clip" model 11 . Thus, in addition to excess preload, the recipient heart is exposed to excess afterload due to systemic vasoconstriction through RAAS hormones and endothelin 1, inducing conditions such as vascular obstructive lesions, hypertension, and cardiomyopathy. Additionally, due to the effects of RAAS hormones in inducing myocardial fibrosis and thickening, the recipient may also develop a condition akin to fetal cardiomyopathy 12 . Such hemodynamics and the endocrine environment are considered to be the origin of the various circulatory disorders in both donor and recipient 13 (Fig. 1) .
Cardiovascular Complications Observed in TTTS
The aforementioned hemodynamics reflect the various cardiac complications that arise in TTTS. In particular, the distinctive cardiac complications in the recipient are of particular interest. Cardiovascular conditions that stem from a combination of volume overload from increased circulating blood volume and pressure overload from hypertension or outflow tract impairment are the most common complications in the recipient. Highly-frequent complications include myocardial hypertrophy, atrioventricular valve regurgitation, and persistent pulmonary hypertension of the newborn, and they have been considered not to be associated with a structural anomaly 14 .
However, there are cases in which the condition has progressed to pulmonary valve stenosis or pulmonary atresia (including functional pulmonary atresia), requiring surgical or catheter treatment in severe cases, and this, together with its etiology, has consequently attracted interest 15 . Although cardiac complications are not as common in donors as in recipients, complications such as aortic coarctation are rather distinctive in donors based on the flow theory 16 , where there is poor aorta growth, reflecting the hemodynamics of a decreased systemic blood flow 17 .
It is traditionally known that twins have a greater rate which is activated in an ischemic condition, has attracted attention 19 , indicating that the hemodynamic state itself plays a key role in the onset of heart diseases in TTTS.
Cardiovascular Complications Observed in the Recipient 1. Myocardial Hypertrophy (Hypertrophic Cardiomyopathy)
In our previous survey, myocardial hypertrophy was observed on examination in most TTTS recipients during the fetal and postnatal stages 20 . Others have also reported that the incidence of myocardial hypertrophy during the fetal age is high, at about 50% 21 Table 2 ). Each parameter was given a numeric value based on the degree of severity of the finding with a total maximum of 20 points. CV score was graded to four degree for severity of cardiovascular abnormality. Unlike Quintero's staging, which is largely based on donor characteristics such as abnormal blood flow, this method evaluates the recipient's cardiac complications, aiming to classify the TTTS severity with greater accuracy. In heart failure pathology that progresses from the fetal stage as described, ventricular dilatation caused by myocardial hypertrophy has been emphasized, and this is measured by the myocardial performance index (MPI, Tei index) 23 . Despite their poor postnatal condition, many of these recipients with myocardial hypertrophy present with hypertension at birth. Furthermore, most recipients show cardiac dilatation with a cardiothoracic ratio (CTR) ! 60% on chest X-ray. Echocardiography shows myocardial hypertrophy that exceeds the normal myocardial wall thickness (adjusted to body weight) by +2SD and marked tricuspid regurgitation (Fig. 2) . Although the left ventricular ejection fraction is typically within the normal range, some show early stages of decreased contractile force, and myocardial hypertrophy emerges in these cases once the contractile force is improved. Myocardial hypertrophy is known to normalize in 10 days to 2 months, indicating its characteristic reversible nature 14 .
Autopsy examination has shown a narrowing of the ventricular lumen due to thickening of the ventricular septum and posterior wall, and histopathological examination has shown distinctive myocardial hypertrophy, and in part endocardial fibroelastosis 3, 24 . (Fig. 3) 
Pulmonary Artery Stenosis and Atresia (Fig. 4)
As cardiac complications in the recipient, severe pulmonary artery stenosis and atresia do not occur as frequently as the aforementioned myocardial hypertrophy or hydrops fetalis. However, it is postulated that right ventricular outflow tract obstruction and pulmonary valve degeneration and stenosis may occur concomitantly with myocardial hypertrophy because they occur specifically in the recipient. Their severity varies, and some serious cases require pulmonary valvotomy using a balloon 25, 26 . The authors have also treated two cases where balloon pulmonary valvotomy was required. It has been hypothesized that 15 pulmonary artery stenosis develops in the TTTS recipient through an increase in systemic vascular resistance due to augmented vascular resistance in the umbilical artery, increasing the ventricular pressure, especially the right ventricular pressure. This causes right ventricular hypertrophy and tricuspid regurgitation, hindering forward ejection from the right ventricle, thereby inducing pulmonary artery stenosis and atresia. In the authors' experience, it is observed in 5% of recipients, similar to the incidence reported by others 27, 28 . , the pressure gradient between the right ventricle (RV) and the right atrium (RA) are calculated to be 70 mmHg, which means considerably high RV pressure as a fetus. It is recognized to be the cause of the recipient's fetal hydrops. Fig. 6 A fetal sonography of a representative critical twin to twin transfusion syndrome: The polyhydroamnios of a recipient (the larger twin) and the oligohydroamnios of a donor (the smaller twin). A donor is stuck on the uterine wall and the recipient has fetal hydrops and ascites.
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Atrial Septal Defect
The postulated mechanism for the onset of this condition is as follows: first, there is a synergistic effect of high-output heart failure and right ventricular outflow tract obstructive lesions in the recipient, followed by an increase in shunt via the foramen ovale, thereby having a destructive effect on the atrial septum. However, it is actually unclear whether the atrial septal defect is due to a septal tissue defect or enlargement associated with increased shunt flow 18 .
Hydrops Fetalis
Hydrops fetalis is observed very frequently in the recipient from the fetal stage. Fetal hypertension has been highlighted as its mechanism, and the baseline disease state is considered to involve a secondary hypertensive myocardial hypertrophy and hypertensive polyuria (polyhydramnios). In cases with atrioventricular valve regurgitation, fetal heart failure occurs, progressing to hydrops fetalis (Fig. 5) 20 . The signs of fetal heart failure progress from subcutaneous edema, ascites, and pericardial effusion to pleural effusion, leading to severe hydrops fetalis( Fig. 6) . This condition poses a threat of intrauterine fetal death and requires neonatal treatment after delivery, although complications caused by prematurity can be lethal in markedly preterm births, creating extreme difficulties in treatment.
Rare Complications
Left ventricular outflow tract obstruction ( Fig. 7) In marked cases of hypertrophic cardiomyopathy, left ventricular outflow tract obstruction may appear together with right ventricular outflow tract obstruction. The hemodynamics in this situation are similar to those in Ventricular aneurysm and pericardial effusion ( Fig. 
8)
In the authors' experience, bilateral lung retractions were observed in a recipient due to a large volume of pericardial effusion, and a thin-walled ventricular aneu-rysm that communicated with the right ventricular apex was also present. Autopsy findings showed hemorrhagic pericardial effusion and a fully-thrombosed ventricular aneurysm. The aneurysm histologically showed severe myocardial damage and marked fibrosis 29 . Although advanced myocardial ischemia has been postulated to be its trigger, a clear cause has yet to be established.
Cardiovascular Complications of Fetoscopic Laser
Photocoagulation of Placental Anastomoses (Fig. 9 ) Although selective FLP to treat placental anastomoses can be performed only at a limited number of institutions at the present time, it is a curative method by which the cause of TTTS is eliminated. It is also expected to be a therapeutic method that improves the prognosis of TTTS. In Japan, the procedure has been performed increasingly more frequently, and positive neurological outcomes have been achieved 30, 31 . Recent reports have indicated that the aforementioned cardiovascular disorders can remain even after FLP treatment, and there are frequently observed right side cardiac anomalies in the recipient, appeared as pulmonary artery stenosis and functional atresia 7, 32, 33 . The authors have also experienced cases where functional pulmonary valve atresia developed after birth, similar to reports that described a right-side circular shunt where the ductus arteriosus flow also had a left-to-right shunt due to the presence of pulmonary artery regurgitation and tricuspid regurgitation from the fetal stage 34, 35 . As described, cardiovascular complications can remain even after curative therapy for TTTS. These 
